Acute leukemia is a hematologic malignancy originating from hematopoietic stem and progenitor cells in the bone marrow, characterized by recurrent fever, anemia, and hepatosplenomegaly. Leukemia is the most common malignancy in children and about 53.4% of the newly developed leukemia cases are in adolescents ...
Acute leukemia is a hematologic malignancy originating from hematopoietic stem and progenitor cells in the bone marrow, characterized by recurrent fever, anemia, and hepatosplenomegaly. Leukemia is the most common malignancy in children and about 53.4% of the newly developed leukemia cases are in adolescents & children under 20 years old. Recently, advances in the development of targeted agents, cellular immunotherapy and hematopoietic stem cell transplantation have significantly improved the prognosis of leukemia patients, but there are still some cases of relapsed or refractory leukemia, and the prognosis of these patients is relatively worse. Metabolic reprogramming has been increasingly demonstrated as a mechanism by which leukemic cells evade immune surveillance and enhance their proliferation. Leukemic cells may have altered biosynthesis, redox and energy utilization pathways. There are clinical trials that confirm the therapeutic potential of targeting the abnormal metabolic pathways of leukemic cells.
The aim of this Research Topic is to gather contributions from a wide array of scientists currently developing and working with diverse models for acute leukemia, with the focus on the metabolism reprogramming involved in the initiation and development of leukemia, so as to provide a theoretical basis for more accurate clinical therapy.
We encourage prospective authors to focus their manuscripts but not limited to the following subtopics:
- Genetic and biochemical approaches to understand mechanism of metabolism reprogramming in acute leukemia.
- Novel approaches targeting metabolism pathway of acute leukemia.
- Interdisciplinary research based on organoids or novel drug delivery systems.
Keywords:
Hematological malignancy, Acute leukemia, Metabolism, Drug resistance, Targeted therapies
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.